Sex hormones are important throughout our life for maintaining numerous aspects of our health and vitality. They are involved in maintaining our basal metabolism, maintenance of muscle mass and mobility, mental health, cardiovascular health, and immune function.
There is a natural biological decline in these functions over the course of our life that needs to be respected and acknowledged (especially in the setting of multiple high-risk comorbid medical conditions).
Some people have an abnormal early decline that predisposes those individuals to obesity, diabetes, cardiovascular disease, and various types of cancer (among other risks). For these patients, we have partnered with Hormone Therapy Centers of America to provide the safest and most effective method of bioidentical hormone therapy available on the market today.
There are two main classes of hormone replacement therapy available: bioidentical and nonbioidentical or pharmaceutical. The difference between these types lies in the chemical structure of the hormones being administered.
Bioidentical hormones are hormones that are derived from natural sources that have the same chemical structure and function as those that appear in the human body. With regards to the sex hormones, this is primarily the chemicals that are commonly referred to as testosterone, estrogen, and progesterone. Because they occur naturally in nature, these substances cannot be patented for sale and distribution.
Non-bioidentical hormones are chemicals that are manufactured to function similarly to our body’s naturally occurring hormones, but they have a slightly altered chemical function which allows for industry to patent them.
In reviewing the available data from clinical trials that have involved these two types of hormone therapy, we have found that bioidentical hormone therapy has a much safer overall risk profile when compared to the chemically altered forms. The prevailing theory for this is that the chemical alterations performed to allow for the medications to be patent have altered the activity of these chemicals in the body, leading to an increased adverse risk profile for some of these medications. Because of these findings, we have chosen to administer bioidentical hormones in our practice for our patients with appropriately diagnosed sex-hormone deficiencies in order to treat the symptoms and risk factors noted above.
Hormone therapy can be administered by oral, topical/transdermal, injectable, and subcutaneous pellet routes. While none of these routes can truly recreate the body’s natural intrinsic regulation and production, subcutaneous pellet therapy has been found to create the most consistent and steady levels in the body, which allows these levels to monitored and adjusted accordingly for safety.
We are proud to partner with HTCA to provide our bioidentical hormone program. They have developed a reputation for safety, consistency, and quality that gives us the best product available for our patients. This has been developed by combining quality pharmacy partnerships, a proprietary dosing site for safety and effectiveness, and a proven monitoring algorithm for patient safety. For more information on HTCA, please visit their website at ht-ca.com.